Article Text

PDF
Paper
Prescription preferences in antipsychotics and attitude towards the pharmaceutical industry in Belgium
  1. Stijn Cleymans1,
  2. Manuel Morrens1,2,
  3. Chris Bervoets1,3
  1. 1 Collaborative Antwerp Psychiatric Research Institute (CAPRI), Universiteit Antwerpen, Antwerpen, Belgium
  2. 2 Psychiatric Hospital Duffel, Duffel, Belgium
  3. 3 Universitary Psychiatric Center KULEUVEN, Leuven, Belgium
  1. Correspondence to Dr Stijn Cleymans, Collaborative Antwerp Psychiatric Research Institute (CAPRI), Universiteit Antwerpen, Campus Drie Eiken—gebouw R—D.R.327, Universiteitsplein 1, Antwerpen 2610, Belgium; stijn.cleymans{at}student.uantwerpen.be

Abstract

Objectives The number of antipsychotic prescriptions are increasing rapidly worldwide, a trend which is mainly driven by the steep rise in second-generation antipsychotic (SGA) prescriptions. However, the success of SGA, compared with the older first-generation antipsychotics (FGAs), cannot be explained by evidence. Several studies concluded on equal efficacy of FGA and SGA on positive, negative and cognitive symptoms of schizophrenia. Next to that, the influence of the pharmaceutical industry on prescription behaviour has drawn considerable interest. Therefore, the relationship between antipsychotic prescription patterns and exposure to information directly provided by pharmaceutical companies was studied.

Methods A cross-sectional online survey, addressing psychiatrists, general practitioners (GPs) and trainees in Flanders, was carried out. Respondents were questioned about their prescription behaviour, opinion about efficacy of SGA versus FGA and the nature and frequency of their contact with the pharmaceutical industry. Using Spearman's rank correlations and χ2 tests, the relationship between different variables and group differences were examined.

Results Psychiatrists, GPs and trainees in Flanders clearly favour olanzapine and risperidone, followed by quetiapine and aripiprazole above all other agents. This behaviour is supported by the conviction that SGAs have superior efficacy and a more benign side effect profile, compared with FGA. Frequent contact with drug representatives is correlated with a preference of SGA over FGA. 41% of the respondents acknowledge to be influenced by the pharmaceutical industry, which is more than that previously reported.

  • Clinical Ethics
  • Demographic Surveys/Attitudes
  • Drugs and Drug Industry
  • Health Care Economics
  • Psychiatry

Statistics from Altmetric.com

Footnotes

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.